UNION CITY, Ga.--(BUSINESS WIRE)--Dendreon Pharmaceuticals, a commercial-stage biopharmaceutical company and pioneer in the development of immunotherapy, has signed a 10-year lease agreement to maintain its 155,000 square foot immunotherapy manufacturing facility (IMF) in Union City, located just outside the Atlanta Metro area.
“Dendreon has been a proud member of the greater Atlanta community since 2009, and we are thrilled to extend our presence here,” said Christina Yi, chief operations officer at Dendreon. “Over the past 10 years, we have grown locally, building key relationships that allow us to sustain our unique business. We look forward to continuing to attract diverse local talent who will help us bring PROVENGE® (sipuleucel-T) to more men with advanced prostate cancer.”
Hans Kemp and Scott Clayton with Cresa Global Inc. represented Dendreon in the lease transaction. In addition to the Union City site, Dendreon’s headquarters and a West Coast-based IMF are located in Seal Beach, Calif.; operations and medical organizations are in Seattle, Wash.
Dendreon is a commercial-stage biopharmaceutical company and is the only company in the U.S. with an FDA-approved active cellular immunotherapy for a solid tumor. Dendreon’s flagship product, PROVENGE® (sipuleucel-T), was the first FDA-approved immunotherapy made from a patient’s own immune cells. Nearly 40,000 men with advanced prostate cancer have been prescribed PROVENGE in the U.S. since 2010. Dendreon also is evaluating the use of PROVENGE in early-stage prostate cancer, with the hope of curing more men of the disease. Dendreon is headquartered in Seal Beach, Calif. For more information, please visit www.dendreon.com.